AAAAAA
Results:
1-10
|
Results: 10
Authors:
Vincent, F
Ceraline, J
Goldblum, S
Klein-Soyer, C
Bergerat, JP
Citation: F. Vincent et al., A new flow cytometric method to follow DNA gap filling during nucleotide excision repair of UVc-induced damage, CYTOMETRY, 45(2), 2001, pp. 96-101
Authors:
Limacher, JM
Frebourg, T
Natarajan-Ame, S
Bergerat, JP
Citation: Jm. Limacher et al., Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome, INT J CANC, 96(4), 2001, pp. 238-242
Authors:
Deplanque, G
Ceraline, J
Mah-Becherel, MCM
Cazenave, JP
Bergerat, JP
Klein-Soyer, C
Citation: G. Deplanque et al., Caffeine and the G2/M block override: A concept resulting from a misleading cell kinetic delay, independent of functional p53, INT J CANC, 94(3), 2001, pp. 363-369
Authors:
Kurtz, JE
Deplanque, G
Borel, C
Mathelin, C
Prevost, G
Poulin, G
Barats, JC
Bergerat, JP
Chapelle-Marcillac, I
Bardonnet, M
Dufour, P
Citation: Je. Kurtz et al., Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer, ANN ONCOL, 11(2), 2000, pp. 229-230
Authors:
Deplanque, G
Vincent, F
Mah-Becherel, MCM
Cazenave, JP
Bergerat, JP
Klein-Soyer, C
Citation: G. Deplanque et al., Caffeine does not cause override of the G2/M block induced by UVc or gammaradiation in normal human skin fibroblasts, BR J CANC, 83(3), 2000, pp. 346-353
Authors:
Hamid, D
Duclos, B
Barats, JC
Prevot, G
Hummel, M
Baldauf, JJ
Brettes, P
Giron, C
Maloisel, F
Lioure, B
Herbrecht, R
Audhuy, B
Bergerat, JP
Oberling, F
Dufour, P
Citation: D. Hamid et al., Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery, INT J GYN C, 9(3), 1999, pp. 231-237
Authors:
Bonneterre, J
Spielman, M
Guastalla, JP
Marty, M
Viens, P
Chollet, P
Roche, H
Fumoleau, P
Mauriac, L
Bourgeois, H
Namer, M
Bergerat, JP
Misset, JL
Trandafir, L
Mahjoubi, M
Citation: J. Bonneterre et al., Efficacy and safety of docetaxel (Taxotere (TM)) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience, EUR J CANC, 35(10), 1999, pp. 1431-1439
Authors:
Escudier, B
Chevreau, C
Lasset, C
Douillard, JY
Ravaud, A
Fabbro, M
Caty, A
Rossi, JF
Viens, P
Bergerat, JP
Savary, J
Negrier, S
Citation: B. Escudier et al., Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?, J CL ONCOL, 17(7), 1999, pp. 2039-2043
Authors:
Kurtz, JE
Deplanque, G
Duclos, B
Giron, C
Lioure, B
Limacher, JM
Herbrecht, R
Laplace, A
Bergerat, JP
Dufour, P
Citation: Je. Kurtz et al., A phase I/II study of dose-escalated ifosfamide plus carboplatin combination for advanced ovarian carcinoma, ONKOLOGIE, 22(3), 1999, pp. 212-215
Authors:
Vincent, F
Deplanque, G
Ceraline, J
Duclos, B
Bergerat, JP
Citation: F. Vincent et al., p53-independent regulation of cyclin B1 in normal human fibroblasts duringUV-induced G2-arrest, BIO CELL, 91(9), 1999, pp. 665-674
Risultati:
1-10
|